Figure 2 from Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

Patient outcomes on elacestrant by prior lines of therapy. TTNT (A), TTD (B), and OS (C) on elacestrant are depicted comparing differences in outcomes by the number of prior lines of metastatic therapy. Patients who received elacestrant after one or fewer prior lines are displayed in blue, after two prior lines are displayed in red, and after three or more prior lines are displayed in green. Adjusted HR and corresponding 95% CI are displayed comparing patients with two prior lines and three or more prior lines with those with one or fewer prior lines of metastatic therapy before elacestrant initiation. Vertical hash marks denote a censored patient event. CL, confidence limit; pts, patients.